News & Updates

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

In convalescent patients with the coronavirus disease 2019 (COVID-19), humoral and cellular responses against the SARS-CoV-2 virus remain robust at 1 year after infection, according to a recent study. However, a notable dysfunction in CD4+ T cells emphasizes the need for vaccination to prevent reinfection.

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

A quick, objective testing kit for daily self-assessment of olfactory and gustatory function can effectively measure smell and taste losses associated with COVID-19, as shown in a study.